Targeted Telerehabilitation Following Curative Intent Therapy of Lung Cancer
Lung cancer is the second-most commonly diagnosed cancer among U.S. Veterans. Substantial advances have been made in early detection through screening and treatment. The longevity of Veterans following lung cancer diagnosis and treatment has increased. Following treatment however, many Veterans experience increased symptom burden, particularly in shortness of breath, fatigue, and fear/anxiety about lung cancer, and impairments in physical and psychosocial functioning. Rehabilitation services are needed to address these survivorship challenges. This study will evaluate multi-targeted telerehabilitation with Veterans following lung cancer treatment, with goals to reduce symptom burden, improve physical and psychosocial function, and enhance health-related quality of life. This research will also develop the career of a physician researcher to acquire expertise in rehabilitation for many Veteran survivors of lung and other cancers.
Checked against the public recordLast updated Jan 27, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Supportive Care
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- VA Office of Research and Development
- Interventions being studied
- Behavioral: Targeted-telerehabilitation; Behavioral: Waitlist
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Adult Veterans with a history of stage I-III A/B lung cancer, and * Completed curative intent therapy (i.e., lung cancer resection surgery, definitive radiation, or concurrent chemoradiation) within 1-6 months Exclusion Criteria: * Adult Veterans with any comorbid conditions that preclude participation in exercise and telerehabilitation: * Orthopedic conditions (e.g., bilateral below-knee amputation), or * Severe cardiopulmonary disease (e.g., unstable arrhythmias including ventricular tachycardia, heart failure with systolic ejection fraction \< 25%, chronic hypoxemia needing \> 5 L/min oxygen supplementation at rest), or * Inability to follow directions or provide informed consent (e.g., moderate to severe dementia), or * Enrolled in hospice, or * With an estimated life expectancy of \< 6 months
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Rocky Mountain Regional VA Medical Center, Aurora, COAurora, Colorado
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 27, 2026. Always confirm current availability with the study team.